Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest presents aclidinium results at ERS

Forest presents aclidinium results at ERS

20th September 2007

Forest Laboratories has presented study results for its aclidinium bromide at the European Respiratory Society (ERS) Annual Congress in Stockholm.

The phase IIa trial showed that single doses of inhaled aclidinium produced a significant bronchodilatory response in 17 patients with COPD.

Forest announced the results which showed that measures of the lung function, FEV1 and FVC values, were increased with all doses of aclidinium over a 24-hour time period, when compared to placebo.

Also it was observed that the onset of bronchodilation emerged as early as 15 minutes after aclidinium treatment and this effect was sustained for at least 24 hours.

Lawrence S Olanoff, president and chief operating officer, stressed the need for new treatment options due to the increasing “disease burden” of COPD in the US.

“These phase II data reinforce our belief that aclidinium has the potential to be a significant addition to the existing armamentarium of COPD treatments,” he said.

Aclidinium is currently in phase III clinical trials in COPD and was licensed by Forest from Spanish pharmaceutical company, Almirall.

Earlier this week, Forest Laboratories signed a co-development and marketing agreement with Microbia relating to linaclotide, its compound currently being investigated as a treatment for gastrointestinal disorders including constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.